D. Masterman

发表

Association of single-nucleotide polymorphisms of the tau gene with late-onset Parkinson disease.

J. Haines, M. Pericak-Vance, J. Jankovic, 2001, JAMA.

Neuropsychiatric symptoms and quality of life in Alzheimer disease.

J. Cummings, D. Masterman, I. Shin, 2005, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

Depression in patients with Parkinson's disease

J. Cummings, D. Masterman, J L Cummings, 1999, International journal of geriatric psychiatry.

Ocrelizumab versus Interferon Beta‐1a in Relapsing Multiple Sclerosis

A. Traboulsee, L. Kappos, G. Comi, 2017, The New England journal of medicine.

Sensitivity, Specificity, and Positive Predictive Value of Technetium 99-HMPAO SPECT in Discriminating Alzheimer's Disease from other Dementias

J. Cummings, M. Mendez, D. Masterman, 1997, Journal of geriatric psychiatry and neurology.

Regression to the mean: implications for clinical trials of psychotropic agents in dementia.

L. Thal, J. Cummings, A. Gamst, 2004, Current Alzheimer research.

Role of Cholinesterase Inhibitors in Managing Behavioral Problems in Alzheimer's Disease.

D. Masterman, 2004, Primary care companion to the Journal of clinical psychiatry.

Evaluation of no evidence of progression using composite outcome measures, in patients with primary progressive multiple sclerosis in the ORATORIO trial

D. Arnold, X. Montalban, A. Bar-Or, 2016 .

The α-synuclein gene is not a major risk factor in familial Parkinson disease

J. Haines, M. Pericak-Vance, J. Jankovic, 1999, Neurogenetics.

P 1 Effect of ocrelizumab on magnetic resonance imaging markers of neurodegeneration in patients with relapsing multiple sclerosis – analysis of the phase III, double-blind, double-dummy, interferon beta-1a- controlled OPERA I and OPERA II studies

G. Comi, D. Arnold, A. Bar-Or, 2017, Clinical Neurophysiology.

Efficacy and safety of ocrelizumab in relapsing multiple sclerosis: Results of the IFN-β-1a-controlled, double-blind, Phase III OPERA I and II studies

D. Arnold, L. Kappos, A. Bar-Or, 2016 .

Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis - results of the placebo-controlled, double-blind, Phase III ORATORIO study

D. Arnold, X. Montalban, A. Bar-Or, 2015 .

Clinical characteristics in early Parkinson's disease in a central California population‐based study

Beate Ritz, B. Ritz, J. Bronstein, 2005, Movement disorders : official journal of the Movement Disorder Society.

A potential role of the curry spice curcumin in Alzheimer's disease.

J. Cummings, J. Ringman, G. Cole, 2005, Current Alzheimer research.

Oral curcumin for Alzheimer's disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study

Catherine A. Sugar, T. Montine, E. Teng, 2012, Alzheimer's Research & Therapy.

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

Bernhard Hemmer, Ludwig Kappos, Stephen L. Hauser, 2017, The New England journal of medicine.

Apathy is not depression.

Jane S. Paulsen, I Litvan, B L Miller, 1998, The Journal of neuropsychiatry and clinical neurosciences.

Encephalitis lethargica: Lessons for neuropsychiatry

J. Cummings, D. Masterman, T. Chow, 2001 .

Delayed internal capsule infarctions following radiofrequency pallidotomy. Report of three cases.

J. Bronstein, D. Masterman, A. D. De Salles, 1997, Journal of neurosurgery.

Frontal-subcortical circuits: the anatomic basis of executive, social and motivated behaviors

J. Cummings, D. Masterman, J L Cummings, 1997, Journal of psychopharmacology.

Treatment of the neuropsychiatric symptoms in Alzheimer's disease.

D. Masterman, 2003, Journal of the American Medical Directors Association.

Intact implicit habit learning in Alzheimer's disease.

B. Knowlton, Laura L. Eldridge, D. Masterman, 2002, Behavioral neuroscience.

Mild Cognitive Impairment is Associated With Characteristic Neuropsychiatric Symptoms

J. Cummings, D. Masterman, L. Fairbanks, 2004, Alzheimer disease and associated disorders.

Complete genomic screen in Parkinson disease: evidence for multiple genes.

J. Haines, M. Pericak-Vance, J. Jankovic, 2001, JAMA.

Revision of the criteria for Alzheimer's disease: A symposium

Ronald C. Petersen, Richard Frank, Michael Gold, 2011, Alzheimer's & Dementia.

Complete genomic screen in Parkinson Disease

J. Haines, J. Jankovic, A. Roses, 2001 .

Living with Parkinson's disease.

J. Bronstein, D. Masterman, A. D. De Salles, 1996, The New England journal of medicine.

Dementia with Lewy bodies

D. Benson, M. Mega, J. Cummings, 1996, Neurology.

Cholinesterase inhibitors in the treatment of Alzheimer's disease and related dementias.

D. Masterman, 2004, Clinics in geriatric medicine.

Efficacy of Olanzapine in the Treatment of Psychosis in Dementia with Lewy Bodies

J. Cummings, D. Masterman, W. S. Clark, 2002, Dementia and Geriatric Cognitive Disorders.

Immunoglobulin M oligoclonal bands: Biomarker of targetable inflammation in primary progressive multiple sclerosis

X. Montalban, A. Bar-Or, D. Masterman, 2014, Annals of neurology.

Analysis of probabilistic classification learning in patients with Parkinson's disease before and after pallidotomy surgery.

Barbara J Knowlton, Antonio De Salles, B. Knowlton, 2003, Learning & memory.

The alpha-synuclein gene is not a major risk factor in familial Parkinson disease.

J. Haines, M. Pericak-Vance, J. Jankovic, 1999, Neurogenetics.

P 2 Effect of ocrelizumab on humoral immunity markers in the phase iii, double-blind, double-dummy, IFN β -1a–controlled OPERA I and OPERA II studies

G. Comi, D. Arnold, L. Kappos, 2017, Clinical Neurophysiology.

A case of semantic variant primary progressive aphasia with severe insular atrophy

H. Vinters, M. Mendez, D. Masterman, 2012, Neurocase.

Motor, cognitive, and behavioral performance following unilateral ventroposterior pallidotomy for Parkinson disease.

R. Baloh, E. Behnke, J. Bronstein, 1998, Archives of neurology.

Cognitive and metabolic responses to metrifonate therapy in Alzheimer disease.

A W Toga, M E Phelps, I D Dinov, 2001, Neuropsychiatry, neuropsychology, and behavioral neurology.

Staged bilateral pallidotomy for treatment of Parkinson disease.

E. Behnke, J. Bronstein, A. DeSalles, 2001, Journal of neurosurgery.

Evidence for Multiple Genes

Vance, J. Haines, J. Jankovic, 2001 .

Can We Use Blood Biomarkers as Entry Criteria and for Monitoring Drug Treatment Effects in Clinical Trials? A Report from the EU/US CTAD Task Force

Gavin J. Cook, M. Gallagher, M. Carrillo, 2023, The Journal of Prevention of Alzheimer's Disease.

Frontal-subcortical circuits : the anatomic basis of executive , social and motivated behaviors

J. Cummings, D. Masterman, 2006 .

Depression in patients with Parkinson's disease

J. Cummings, D. Masterman, 1999, International journal of geriatric psychiatry.

A Rationale for Curcuminoids for the Prevention or Treatment of Alzheimers Disease

J. Cummings, G. Cole, S. Frautschy, 2003 .

Assessment of treatment-associated changes in behavior and cholinergic therapy of neuropsychiatric symptoms in Alzheimer's disease.

J. Cummings, D. Masterman, 1998, The Journal of clinical psychiatry.

Week 144 Results of a Phase II, Randomized, Multicenter Trial Assessing the Safety and Efficacy of Ocrelizumab in Patients with Relapsing–Remitting Multiple Sclerosis (RRMS) (S31.004)

F. Barkhof, L. Kappos, P. Calabresi, 2013 .

Dementia with Lewy bodies

Jeffrey L. Cummings, Douglas W. Scharre, Michael S. Mega, 1996, Neurology.

Strategies for analysing behavioural data in clinical trials involving patients with Alzheimer's disease.

J. Cummings, D. Masterman, L. Fairbanks, 1999, The international journal of neuropsychopharmacology.